| Identification | Back Directory | [Name]
MK-2048 | [CAS]
869901-69-9 | [Synonyms]
CS-1529
MK-2048 USP/EP/BP
(S)-2-(3-chloro-4-fluorobenzyl)-8-ethyl-10-hydroxy-N,6-diMethyl-1,9-dioxo-1,2,6,7,8,9-hexahydropyrazino[1',2':1,5]pyrrolo[2,3-d]pyridazine-4-carboxaMide
(6S)-2-[(3-Chloro-4-fluorophenyl)methyl]-8-ethyl-1,2,6,7,8,9-hexahydro-10-hydroxy-N,6-dimethyl-1,9-dioxopyrazino[1',2':1,5]pyrrolo[2,3-d]pyridazine-4-carboxamide
Pyrazino[1',2':1,5]pyrrolo[2,3-d]pyridazine-4-carboxamide, 2-[(3-chloro-4-fluorophenyl)methyl]-8-ethyl-1,2,6,7,8,9-hexahydro-10-hydroxy-N,6-dimethyl-1,9-dioxo-, (6S)- | [Molecular Formula]
C22H24FN5O4 | [MOL File]
869901-69-9.mol | [Molecular Weight]
441.455 |
| Chemical Properties | Back Directory | [density ]
1.55 | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO > 10 mM | [form ]
Powder | [pka]
6.30±0.40(Predicted) | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Uses]
MK-2048 represents a prototype second generation integrase strand transfer inhibitor (INSTI), it was developed with the goal of retaining activity against viruses containing mutations assiciated with
resistance of first-generation INSTIs, raltegravir (R100312). MK-2048 exhibits inhibitory activity towards HIV integrase and towards HIV replication. It is four times more effective in inhibiting HIV
enzyme integrase than the first generation inhibitor, raltegravir. | [target]
subtype B integrase |
|
| Company Name: |
NCE Biomedical Co.,Ltd.
|
| Tel: |
4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988 |
| Website: |
www.is0513.com/ShowSupplierProductsList15748/0.htm |
| Company Name: |
SPIRO PHARMA
|
| Tel: |
|
| Website: |
www.spiropharma.com.cn |
|